Skip to main content
. 2016 Jun 28;6(9):e00505. doi: 10.1002/brb3.505

Figure 3.

Figure 3

Pooled efficacy data from pivotal phase 3 studies 304 (French et al. 2012), 305 (French et al. 2013), and 306 (Krauss et al. 2012). (A) Median percentage change in seizure frequency per 28 days of treatment versus baseline; (B) 50% responder rates; and (C) median percentage change for complex partial seizures plus secondarily generalized seizures (Steinhoff et al. 2013). The subanalysis was not powered for statistical analysis.